



PBS restrictions for T2DM medicines - summary tables

1 April 2025

The following tables provide an abridged description of the revised Pharmaceutical Benefits Scheme (PBS) restrictions for type 2 diabetes mellitus (T2DM) medicines.

Table 1. PBS Unrestricted medicines and Restricted Benefit medicines for T2DM by class

Class	Drug
<i>Biguanides</i>	Metformin
<i>Sulfonylureas</i>	Glibenclamide
	Gliclazide
	Glimepiride
	Glipizide
<i>Alpha glucosidase inhibitors</i>	Acarbose
<i>Insulins</i>	Insulins, except insulin detemir which is a Restricted Benefit for use in type 1 diabetes mellitus
<i>Thiazolidinediones</i>	Pioglitazone

Table 2. PBS-subsidised combinations of Authority Required T2DM medicines by drug

Key: Green = PBS-subsidised, Red = NOT PBS-subsidised, Orange = PBS-subsidised with contraindication/intolerance requirements.

Class	Drug (Brand name)	Dual therapy with Met or Su	Triple therapy with Met + Su	Dual/triple therapy with Ins +/- Met	Triple therapy with Met + SGLT2i	Triple therapy with Met + DPP4i
DPP4i 'Gliptins'	Alogliptin (Nesina®)	✓ ¹	✓	✓	✓	NA
	Linagliptin (Trajenta®)	✓ ¹	✓	✓	✓ ³	NA
	Saxagliptin (Onglyza®)	✓ ¹	✓	✓	✓ ³	NA
	Sitagliptin (multiple brands)	✓ ¹	✓	✓	✓ ³	NA
	Vildagliptin (Galvus®)	✓ ¹	✓	✓	✓	NA
SGLT2i 'Flozins'	Dapagliflozin (Forxiga®)	✓ ²	✓	✓	NA	✓ ³
	Empagliflozin (Jardiance®)	✓ ²	✓	✓	NA	✓ ³
GLP-1 RAs	Dulaglutide (Trulicity®)	✓ ⁴	✓ ⁴	✓ ⁴	X ⁵	X
	Semaglutide (Ozempic®)	✓ ⁴	✓ ⁴	✓ ⁴	X ⁵	X

Abbreviations: DPP4i = dipeptidyl peptidase-4 inhibitor, Ins = insulin; Met = metformin, NA = Not applicable; SGLT2i = sodium-glucose cotransporter 2 inhibitor, Su = sulfonylurea.

Quadruple therapy: PBS-subsidised quadruple therapy options have not been included for simplicity. DPP4i and SGLT2i are subsidised for use in combination with each other, insulin and other Unrestricted medicines.

60-day prescriptions: All T2DM medicines, except insulins and GLP-1 RAs, are available for 60-day prescriptions. The patient's condition must be stable.

Notes:

1. DPP4i with metformin fixed dose combination (FDC) available - not subsidised for initial therapy.
2. SGLT2i with metformin FDC available. SGLT2i are subsidised for initial T2DM therapy without a glycaemic requirement when used in combination with metformin (unless contraindicated/intolerant) for patients with cardiovascular disease, those at high risk of a cardiovascular event, and for Aboriginal or Torres Strait Islander patients.
3. DPP4i with SGLT2i FDC available - not subsidised for initial therapy.
4. Patient must have a contraindication/intolerance requiring treatment discontinuation to an SGLT2 inhibitor, or the patient must not have achieved a clinically meaningful glycaemic response to an SGLT2 inhibitor. Telephone/electronic authority required for initiation.
5. GLP-1 RAs are not subsidised for use in combination with an SGLT2 inhibitor, except where the SGLT2 inhibitor is prescribed for a different indication (e.g., heart failure or kidney disease) and the patient did not achieve a clinically meaningful glycaemic response to the SGLT2 inhibitor.